Navigation Links
Merck Serono Launches Strategic Venture Capital Fund
Date:3/23/2009

lopment organization.

Companies wishing to submit proposals or receive additional information can contact 'Merck Serono Ventures' at:

http://www.merckserono.com/en/partnering/venture_capital_fund/venture_capital_fund.html

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux(R), cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), infertility (Gonal-f(R), follitropin alfa), endocrine and cardiometabolic disorders (Glucophage(R), metformin); (Concor(R), bisoprolol); (Euthyrox(R), levothyroxine); (Saizen(R) and Serostim(R), somatropin). Not all products are available in all markets.

With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.6 billion in 2008, a history that began in 1668, and a future shaped by 32,800 employees in 59 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA,
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
2. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
3. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
4. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
5. Merck Serono Named as a Top Employer by Science Magazine
6. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
7. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
8. BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance
9. New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
10. Merck & Co., Inc. Named Keynote Sponsor For Diversity Alliance For Sciences Inaugural Conference
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that executives from the company ... of September.  , Pedro Lichtinger ... Renshaw,s 17th Annual Global Investment Conference on Wednesday, September ... Regis Hotel in New York City ...
(Date:8/27/2015)... Aug. 27, 2015 HUYA Bioscience International (HUYA) today ... the Japan Society of HTLV-1, held this week at ... purpose of the Society is to promote research on ... of medical technology and research related to these fields ... "HUYA is proud to support this prestigious conference," ...
(Date:8/27/2015)... MA (PRWEB) , ... August 27, 2015 , ... Inc. ... United States, ranking iLab Solutions as number 1,361 in growth for the three years ... of the top 0.1% fastest-growing privately held organizations in the country. , “We ...
(Date:8/27/2015)... N.C. , Aug. 27, 2015 ... decision by FedEx, UPS and The US Postal ... biological specimens classified as ,select agents, by the ... history of handling these sensitive shipments. ... global transportation regulations, trained and certified personnel to ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... Cell Through In Vivo ... Imaging-, ... ) today introduced Bioware(R) Ultra cell lines,a range of ultra bright light ... cell lines are,10 to 100 times brighter than cell lines created using ...
... Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) announced that ... Nemours Center for Childhood Cancer Research entitled,"Radiation in ... at the American Association for Cancer Research (AACR),Annual ... Diego, California from,April 12-16, 2008., "The combination ...
... Sign Manufacturing and Distribution Agreement, GURGAON, ... Ranbaxy,Pharmaceuticals Inc. (RPI), a wholly owned subsidiary ... it has reached several,agreements with AstraZeneca. Two ... third agreement pertains to Omeprazole 40mg,tablets, and ...
Cached Biology Technology:Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 3Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 3
(Date:8/12/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is proud to announce that iMedNet ... technology platform, has led the way to significant and ... 2015.   Q2 2015 and Q1 2015 were, respectively, ... value sold in the company,s 15 year history.  In ...
(Date:8/10/2015)... and TELTOW, Germany , ... Instruments (SMI), a world leader in Eye Tracking ... completion of its OEM Eye Tracking Platform for integration ... Tracking Platform contains reference designs for seamless integration of ... systems, virtual reality HMDs and augmented reality smart glasses. ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... its damaging effect on the environment and its illegal ... to adverse effects on human health, such as inflammation ... damage and possibly cancer. In a ... journal Environmental Research Letters, researchers took air ...
... pinpoint a small RNA that spurs cells to manufacture a ... Alzheimer,s disease (AD) or other types of neurodegeneration. The study ... of Cell Biology ( www.jcb.org ). Like ... in more than one version. Although scientists have identified numerous ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
Cached Biology News:'E-waste pollution' a threat to human health, new research suggests 2Novel pathway regulating angiogenesis may fight retinal disease, cancers 2
... MAX POWER 500V Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
Biology Products: